Lloyd Klickstein - Aug 19, 2024 Form 3 Insider Report for Adicet Bio, Inc. (ACET)

Role
Director
Signature
/s/ Nick Harvey, Attorney-in-Fact
Stock symbol
ACET
Transactions as of
Aug 19, 2024
Transactions value $
$0
Form type
3
Date filed
8/20/2024, 04:03 PM

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding ACET Common Stock 103K Aug 19, 2024 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding ACET Stock Option (Right to Buy) Aug 19, 2024 Common Stock 80K $2.14 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 1/48th of the shares shall vest on each of the next forty-eight (48) monthly anniversaries of January 13, 2021, provided that the Reporting Person maintains a service relationship with the Issuer as of the applicable vesting dates.
F2 On August 8, 2023, the Issuer's Board of Directors approved an option repricing, effective as of August 14, 2023 (the "Repricing Effective Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. The exercise price of the option is $2.14 per share, representing the fair market value per share of the Issuer's Common Stock on the Repricing Effective Date.

Remarks:

Exhibit List - Exhibit 24 - Power of Attorney